The global GLP-1 agonists weight loss drugs market size was estimated at USD 13.84 billion in 2024 and is projected to reach USD 48.84 billion by 2030, growing at a CAGR of 18.54% from 2025 to 2030. The rapid expansion of this market is largely fueled by the increasing prevalence of obesity worldwide, heightened public awareness about health and wellness, and the proven clinical effectiveness of prominent GLP-1 agonists such as semaglutide—marketed under brand names like Wegovy and Ozempic—and tirzepatide, known commercially as Mounjaro and Zepbound.

Several factors contribute to the accelerating adoption of GLP-1 weight loss therapies. These include ongoing pharmaceutical advancements, favorable regulatory approvals from health authorities, and a growing scope of insurance coverage that makes these drugs more accessible to a wider population. Moreover, the influence of celebrity endorsements and social media campaigns has played a significant role in expanding consumer interest, pushing the market beyond just diabetic patients to encompass a broader audience seeking effective weight management solutions.

Obesity continues to be a major global health challenge and a key driver for the GLP-1 agonists market. In 2022, data shows that around 2.5 billion adults worldwide were classified as overweight, with about 890 million of them falling into the obese category. Additionally, 37 million children under the age of five were reported as overweight. The rise in obesity can largely be attributed to factors such as unhealthy dietary habits, sedentary lifestyles, and environments that promote weight gain (often termed obesogenic environments). Despite these challenges, obesity is considered preventable and manageable through a combination of healthy eating, consistent physical activity, and positive lifestyle modifications. Global health organizations like the World Health Organization (WHO) have emphasized the urgency for collective action, calling for policies aimed at regulating food quality and marketing practices, alongside enhanced health sector interventions to mitigate obesity and its related health risks.

Key Market Trends & Insights:

• In 2024, North America emerged as the dominant region in the GLP-1 agonists weight loss drugs market, capturing the largest revenue share of 75.50%. This strong market presence highlights the region's significant role in driving the global growth of these weight loss therapies. Within North America, the United States accounted for an overwhelming majority of the market, holding a substantial share of 95.23% in 2024. This dominant position is reflective of the country’s advanced healthcare infrastructure, high prevalence of obesity, and widespread adoption of innovative pharmaceutical treatments.

• When analyzing the market by specific drugs, the semaglutide segment, marketed under brand names like Wegovy, led the industry with the highest revenue share, capturing 60.70% of the market in 2024. This dominance is attributed to semaglutide’s proven efficacy, strong clinical support, and growing acceptance among both healthcare providers and patients seeking effective weight management solutions.

• Regarding the route of administration, the parenteral segment—which includes injectable forms of the drug—dominated the market with an impressive revenue share of 92.7% in 2024. This preference is likely due to the effectiveness and bioavailability of injectable GLP-1 agonists compared to other administration methods, making parenteral delivery the preferred choice for most patients and healthcare professionals.

• In terms of distribution channels, retail pharmacies were the leading segment in 2024, accounting for the largest revenue share of 55.46%. This reflects the accessibility and convenience retail pharmacies provide to consumers, allowing patients to obtain GLP-1 agonist medications with ease, which further supports widespread usage and market growth.

Order a free sample PDF of the GLP-1 Agonists Weight Loss Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 13.84 Billion

• 2030 Projected Market Size: USD 48.84 Billion

• CAGR (2025-2030): 18.54%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

The GLP-1 agonists weight loss drugs industry is primarily led by major pharmaceutical companies such as Novo Nordisk, known for its semaglutide products, and Eli Lilly, recognized for tirzepatide, among other industry giants. These leading players are strategically focusing on increasing the availability and accessibility of oral formulations of GLP-1 agonists, as well as expanding their distribution networks. This expansion includes broadening their reach through both hospital and retail pharmacy channels to effectively cater to the rising demand for weight loss medications across various geographical regions. In this competitive landscape, ongoing research and development, coupled with securing regulatory approvals, remain critical factors that enable these companies to sustain their market leadership and competitive edge.

In addition to the established leaders, several emerging companies within the GLP-1 agonists weight loss drugs market are concentrating on specialized segments, such as personalized weight loss therapies tailored to meet the unique needs of individual patients. These newer entrants are also investing in the development of innovative delivery methods, including sublingual tablets and extended-release formulations, aimed at providing patients with more convenient and user-friendly treatment options. Such innovations are particularly important for addressing unmet medical needs, especially in regions where access to treatment is limited or where the adoption of injection-based therapies is hindered by patient preferences or logistical challenges. By targeting these niche areas, emerging players aim to complement existing treatments and contribute to the overall growth and diversification of the market.

Key Players

• Eli Lilly and Company

• Pfizer Inc.

• Novo Nordisk A/S

• Viking Therapeutics

• Structure Therapeutics

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The GLP-1 agonists weight loss drugs market is experiencing rapid growth due to rising obesity rates, increasing health awareness, and strong clinical efficacy of key drugs. Advancements in pharmaceuticals, favorable regulatory support, and expanding insurance coverage are driving wider adoption. Social media and celebrity endorsements are further boosting demand beyond diabetic patients to general weight management. Regional obesity prevalence and healthcare policies will shape market growth, with opportunities varying by geography and demographic trends.